Xarelto

Type: Product
Name: Xarelto
First reported Sep 19 2014 - Updated Sep 19 2014 - 1 reports

Xarelto Makers Seek Dismissal of Cases Brought in Philadelphia, Notes Rottenstein Law Group LLP

According to a report from HarrisMartin dated September 17, the manufacturers of the embattled blood-thinner Xarelto, named as defendants in several lawsuits filed in the Philadelphia County Court of Common Pleas, have moved the court to dismiss those ... [Published BioSpace - Sep 19 2014]
First reported Sep 19 2014 - Updated Sep 19 2014 - 3 reports

Xarelto Lawsuit Defendants Seek to Have Pennsylvania Claims Filed by Out-of-State Plaintiffs Dismissed, Bernstein Liebhard LLP Reports

Defendants in more than a dozen Xarelto lawsuits (http://www.xareltolawsuitcenter.com) currently pending in Pennsylvania’s Philadelphia Court of Common Pleas are attempting to have all claims filed on behalf of out-of-state plaintiffs dismissed, Bernstein ... [Published Bio-Medicine - Sep 19 2014]
First reported Sep 18 2014 - Updated Sep 18 2014 - 1 reports

Bayer brings $12.9B plastics spinoff to Big Pharma's slim-down party

Bayer's drug business is booming. So much so that the German company has decided to put its focus squarely on its life sciences division: It plans to spin off its plastics unit within 18 months, taking a lead from its Big Pharma peers with the industry's ... [Published FiercePharma - Sep 18 2014]
First reported Sep 18 2014 - Updated Sep 18 2014 - 2 reports

Bayer pharma R&D spend to rise after plastics spin-off

Bayer has been giving more details about plans to float its material science division on the stock market and “focus entirely “on life sciences.The flotation will take place within the next 12 to 18 months, and the German conglomerate said a major reason ... [Published Pharma Times - Sep 18 2014]
First reported Sep 18 2014 - Updated Sep 18 2014 - 2 reports

Xarelto(R) Drug Manufacturers Alleged of False and Misleading Advertising that Minimized Risks Potentially Resulting in Adverse Medical Events

PRWebXarelto(R) was originally approved by the U.S. Food and Drug Administration (FDA) in 2011 for open market use. Consumers have since come forward to file complaints and allege personal serious and life-threatening medical conditions were the result ... [Published Wall Street Business Network - Sep 18 2014]
First reported Sep 16 2014 - Updated Sep 17 2014 - 2 reports

Most Treatments for Blood Clots Appear Safe, Effective

TUESDAY, Sept. 16, 2014 (HealthDay News) -- Almost all the various treatment options for blood clots that form in veins are equally safe and effective, new research shows.In exploring the safety and effectiveness of treatments for such blood clots as ... [Published Bio-Medicine - Sep 16 2014]
First reported Sep 17 2014 - Updated Sep 17 2014 - 1 reports

Johnson & Johnson: Slow And Steady Core Holding, But No Discount Here

Summary Johnson & Johnson offers investors a diverse product line, robust free cash flow generation, reliable dividend growth, and low volatility suitable for a core holding. Though the company outperformed expectations in the most recent quarter, yearly ... [Published Seeking Alpha - Sep 17 2014]
First reported Sep 16 2014 - Updated Sep 16 2014 - 1 reports

Xarelto May Lead to Dangerous Bleeding Complications

Xarelto may cause irreversible internal bleeding that can lead to hospitalization and death. What are the risks?Approved by the Food and Drug Administration (FDA) in 2011 , Xarelto is a new type of blood thinner manufactured by Bayer and marketed by Johnson ... [Published I-Newswire - Sep 16 2014]
First reported Sep 10 2014 - Updated Sep 10 2014 - 2 reports

Xarelto Lawsuit Alleges Uncontrollable Bleeding Nearly Cost California Woman Her Life, Bernstein Liebhard LLP Reports

A California woman has filed a new Xarelto lawsuit (http://www.xareltolawsuitcenter.com) that alleges uncontrollable hemorrhaging caused by the blood thinner nearly ended her life, Bernstein Liebhard LLP reports. According to her complaint, which was ... [Published Digital Journal - Sep 10 2014]
First reported Sep 02 2014 - Updated Sep 03 2014 - 4 reports

Bayer Discloses Encouraging Data on Anticoagulant Xarelto

The HealthCare segment at Bayer ( BAYRY - Analyst Report ) announced encouraging results from the X-VeRT study on Xarelto. The study evaluated Xarelto in patients suffering from atrial fibrillation who undergo cardioversion.Results from the study revealed ... [Published Zacks.com - Sep 03 2014]
First reported Aug 31 2014 - Updated Sep 01 2014 - 4 reports

Bayer HealthCare launches three new studies of Xarelto

:24 in Pharmaceutical Company Product News Bayer HealthCare has announced a new expansion of the global clinical development programme for Xarelto, its rivaroxaban-based oral Factor Xa inhibitor therapy. The three new studies will assess the safety and ... [Published Zenopa - Sep 01 2014]
First reported Aug 29 2014 - Updated Aug 29 2014 - 6 reports

Bayer plans 3 new trials to support expanded use of stroke prevention drug Xarelto

FRANKFURT (Reuters) - Germany's Bayer unveiled plans to launch three new studies to expand the uses of its anti-clotting drug Xarelto, one of its top five new medicines.Xarelto, which competes with the Eliquis pill developed by Bristol-Myers Squibb and ... [Published MedCity News - Aug 29 2014]

Quotes

...it would not be proper for these cases to be tried where they were filed," said Rochelle Rottenstein, principal of the Rottenstein Law Group. "That said, if the defendants want the cases out of Philadelphia simply because Philadelphia juries have been historically sympathetic to persons injured by allegedly dangerous drugs, then the argument might be disingenuous. "
...That'll put AbbVie into competition with Gilead Sciences " breakout hep-C star, Sovaldi, which has reeled in nearly $6 billion through the first half of 2014. With debate raging over Sovaldi's pricing, there's a huge opportunity for AbbVie to capitalize in an HCV market that could eclipse $20 billion annually within this decade."
"What we found was, there was a very significant correlation with the lack of Coumadin effectiveness, or lower percent of times in the therapeutic range, and the risk of dementia" Bunch says
"Bayer will continue as an enterprise with an attractive and balanced portfolio and a primary focus on organic growth" Dr Dekkers explained...

More Content

All (195) | News (161) | Reports (0) | Blogs (30) | Audio/Video (0) | Fact Sheets (0) | Press Releases (2)
sort by: Date | Relevance
Xarelto Makers Seek Dismissal of Cases Brought ... [Published BioSpace - Sep 19 2014]
Bayer to spin out material science division [Published PMLive - Sep 19 2014]
3 Best Stocks to Invest in Pharma [Published Motley Fool Discussion Boards - Sep 19 2014]
Xarelto Lawsuit Defendants Seek to Have Pennsyl... [Published Bio-Medicine - Sep 19 2014]
Xarelto Lawsuit Defendants Seek to Have Pennsyl... [Published Presskontakt.se - Sep 19 2014]
Xarelto Lawsuit Defendants Seek to Have Pennsyl... [Published PRWeb - Sep 19 2014]
Investigation Raises Questions About Dabigatran... [Published Pharmacy Practice News - Sep 19 2014]
How Your Blood Thinner Affects Your Brain — And... [Published EverydayHealth.com - Sep 18 2014]
Bayer Plans Stock-Market Listing for Material-S... [Published Mergers & Acquisitions - Sep 18 2014]
Bayer pharma R&D spend to rise after plastics s... [Published Pharma Times - Sep 18 2014]
Bayer plans to focus entirely on Life Science b... [Published Pharma Letter - Sep 18 2014]
Bayer brings $12.9B plastics spinoff to Big Pha... [Published FiercePharma - Sep 18 2014]
Bayer to focus on life sciences as confirms pla... [Published FirstWord Pharma - Sep 18 2014]
Bayer plans to focus entirely on Life Science b... [Published 4 Traders - Sep 18 2014]
Bayer plans stock-market listing for plastics unit [Published Livemint.com - Sep 18 2014]
Bayer Plans Stock-Market Listing for Material-S... [Published Washington Post - Sep 18 2014]
End of an era: Bayer to focus entirely on life ... [Published Pharma Times - Sep 18 2014]
Bayer Plans Stock-Market Listing for Plastics Unit [Published Bloomberg - Sep 18 2014]
Xarelto(R) Drug Manufacturers Alleged of False ... [Published Wall Street Business Network - Sep 18 2014]
Xarelto® Drug Manufacturers Alleged of False an... [Published PRWeb - Sep 18 2014]
Review of thromboembolism treatments finds one ... [Published Cardiovascular Business - Sep 17 2014]
Johnson & Johnson: Slow And Steady Core Holding... [Published Seeking Alpha - Sep 17 2014]
Dr. Pamela Tronetti: A heads up on nosebleeds [Published Florida Today - Sep 17 2014]
Xarelto May Lead to Dangerous Bleeding Complica... [Published I-Newswire - Sep 16 2014]
Most Treatments for Blood Clots Appear Safe, Ef... [Published Bio-Medicine - Sep 16 2014]
Most Treatments for Blood Clots Appear Safe, Ef... [Published US News & World Report - Sep 16 2014]
J&J trims pension benefits for new hires [Published FiercePharma - Sep 12 2014]
Bayer HealthCare's hypertension drug Adempas sh... [Published Zenopa - Sep 12 2014]
Mylan Acquires Rights To Market Aspen’s Arixtra... [Published Bidness Etc - Sep 11 2014]
Mylan Buys Rights to Brand and Generic Injectab... [Published Pharmaceutical Manufacturing Magazine - Sep 11 2014]
1 2 3 4 5 6 7
In Focus
  •  
  •  
  •  
  •  
  •  
  •  
  •  
  •  
  •  
Content Volume
Document Volume
Network
Network

Blogs

sort by: Date | Relevance
Eliquis And Xarelto, Like Pradaxa, Linked To Se... [Published Drug Injury Watch - Sep 05 2014]
Hemorrhages And Gastrointestinal (GI) Bleeds Are Eliquis And Xarelto Side Effects That Can Cause Deaths (Posted by Tom Lamb at DrugInjuryWatch.com ) Eliquis and Xarelto are new anticoagulants, i.e., blood thinners, that -- unlike Coumadin ...
ESC: Xarelto Safe for Cardioverting Afib [Published MedPageToday.com - medical news plus CME for ph ... - Sep 02 2014]
BARCELONA (MedPage Today) -- Switching atrial fibrillation patients awaiting elective cardioversion to rivaroxaban (Xarelto) was as safe as warfarin in that setting. ...
Once-Daily Xarelto® from Bayer Effective and We... [Published Bayer Corporate News - Sep 02 2014]
X-VeRT is the first prospective study of a novel oral anticoagulant in patients with atrial fibrillation who undergo cardioversion / X-VeRT provides important information on the utility and practical advantages of Xarelto in early and delayed cardioversion ...
New Data Show Once-Daily XARELTO® May Be an Alt... [Published PR Newswire: General Business - Sep 02 2014]
BARCELONA, Spain, Sept. 2, 2014 /PRNewswire/ -- Janssen Research & Development, LLC (Janssen) and its development partner, Bayer HealthCare, announced today results from the X-VeRT trial, demonstrating once-daily XARELTO® (rivaroxaban) may be an alternative ...
Janssen expands EXPLORER research program to ev... [Published PBR - News - Sep 01 2014]
Janssen Research & Development (Janssen) and its development partner, Bayer HealthCare, have announced the expansion of the EXPLORER global cardiovascular research program for XARELTO (rivaroxaban) to include additional high-risk patient populations. ...
1 2 3 4 5 6

Press Releases

sort by: Date | Relevance
Keller Rohrback L.L.P. Investigates Life-Threat... [Published GlobeNewswire: Acquisitions News - Aug 26 2014]
Keller Rohrback L.L.P. Investigates Allegations... [Published GlobeNewswire: Acquisitions News - Jul 23 2014]
1
Contact Us
Sales
Support


Freebase CC-BY Some image thumbnails are sourced from Freebase, licensed under CC-BY

Copyright (C) 2014 Silobreaker Ltd. All rights reserved.
The selection and placement of stories and images on any Silobreaker page are determined automatically by a computer program.
The time or date displayed reflects when an article was added to or updated in Silobreaker.